Diagnosis to Delivery
Zur Rose Group acquires TeleClinic, Germany's leading telemedicine provider
- Telemedicine pioneer TeleClinic offering reimbursable consultation services compliant with German national health insurance scheme
- TeleClinic continuously expanding its time to market lead in the post-COVID-19 time
- Telemedicine to form an important element in Zur Rose healthcare ecosystem, serving as additional entry point for digital customer journey
- Doctors are given the opportunity to offer their expertise more flexible and independent of location
- Both companies' core businesses are further strengthened through highly complementary competencies with regard to the electronic prescription (eRx)
The Zur Rose Group has acquired German TeleClinic GmbH, headquartered in Munich, for a purchase price in the mid-double-digit million Euro range. The fast-growing tech company, founded in 2015 by Katharina Jünger, has rapidly achieved the status of the leading telemedicine provider in Germany. TeleClinic's impressive operating parameters and growth demonstrate the vast potential of remote and digital medical services, the global acceptance of which is rapidly expanding as a result of COVID-19 related social distancing constraints.
As pioneer and leading provider of on-demand telemedicine services including digital prescriptions and sick-notes compliant with reimbursement regulations in the German health insurance scheme, TeleClinic is expected to expand its market position as the penetration of digital health services will continue to rise in a post COVID-19 world. Electronic prescriptions (eRx) are expected to be issued for up to 50 per cent of consultations performed on the platform, underlining the highly complementary nature of the acquisition to the eRx strategy of the Zur Rose Group. At TeleClinic, patients receive the e-script via app on their mobile device after expert medical diagnosis, which they can then redeem at an on-site or mail-order pharmacy.
The acquisition of TeleClinic is an important building block, adding complementary telemedicine services to the Zur Rose Healthcare Ecosystem providing seamless and personalized health journeys for consumers. The healthcare platform aims to provide access to best-in-class digital solutions, medications and products in convenient ways. In doing so, Zur Rose pursues the goal of accompanying consumers, including its currently ca. 9 million customers, and enabling them to manage their own health 'in just one click', leading to optimal health outcomes. Telemedicine is a critical, convenient solution in the health journeys of acute as well as chronic conditions and enables the electronic prescription, supporting the e-commerce and marketplace business of the Zur Rose Group. By offering cross-selling potential, TeleClinic will support and leverage the investments Zur Rose has made over the years in its growth strategy and corresponding customer increase.
"As the largest e-commerce pharmacy player rapidly transforming into the preeminent European healthcare ecosystem, our ambition is to empower people to manage their health. With TeleClinic as an integrated part of the Zur Rose Healthcare Ecosystem, we will start offering digital solutions in addition to the medications and pharmacy product portfolio, enabling patients to have better lives," says Walter Oberhänsli, CEO of the Zur Rose Group. Katharina Jünger, Founder and CEO of TeleClinic, emphasizes: "TeleClinic has established itself as a valuable and highly accepted additional channel for patients and doctors alike, extending the reach of consultation. Furthermore, it gives doctors an opportunity to offer their expertise more flexibly and independent of location. We are extremely pleased and excited that TeleClinic will become an integral part of Zur Rose Group's digital Healthcare Ecosystem in Germany and Europe."
The transaction is expected to close end of July 2020.
Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: [email protected], phone: +41 58 810 11 49
Lisa Lüthi, Head of Group Communications
Email: [email protected], phone: +41 52 724 08 14
19 August 2020 Half-Year Results
21 October 2020 Q3 Trading Update
Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and has around seven million active customers in core European markets.
With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.
The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com. Customers which Zur Rose Group supplies either directly or via its partners, including the mail-order business of Apotal.